anti-CD3/anti-ROR1 bispecific T-cell engager (Scripps Research Institute)

N/A

Report date: 2026/03/19 16:53:45

Base Information

Drug Nameanti-CD3/anti-ROR1 bispecific T-cell engager (Scripps Research Institute)

Drug Alias NameROR1 × CD3 bispecific T-cell engager scFv-Fc (Scripps Research Institute)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > T cell engagers

Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsInactive tyrosine-protein kinase transmembrane receptor ROR1 modulators

TargetsT cell surface glycoprotein CD3Inactive tyrosine-protein kinase transmembrane receptor ROR1

Therapy Area/IndicationsKidney NeoplasmsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesThe Scripps Research Institute Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesThe Scripps Research Institute Inc

Active IndicationsN/A

Inactive IndicationsKidney NeoplasmsBreast Neoplasms

Other Information

ATC CodeN/A